IMMUNOCORE HLDGS ADS/1 (6YG) — Capital Reinvestment Ratio
Latest as of June 2025:
0.02x
IMMUNOCORE HLDGS ADS/1 (6YG) has a Capital Reinvestment Ratio of 0.02x as of June 2025, meaning it reinvests 0% of its operating cash flow (€25.96 Million) in capital expenditures (€414.00K). See IMMUNOCORE HLDGS ADS/1 (6YG) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.02x
Capex / Operating Cash Flow
Operating Cash Flow
€25.96 Million
EUR
Capital Expenditures
€414.00K
EUR
Data as of
Jun 2025
Most recent filing
IMMUNOCORE HLDGS ADS/1 Capital Reinvestment Ratio (2023–2024)
This chart tracks IMMUNOCORE HLDGS ADS/1's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for IMMUNOCORE HLDGS ADS/1 (2023–2024)
Year-by-year Capital Reinvestment Ratio for IMMUNOCORE HLDGS ADS/1 from 2023 to 2024. For live market cap and broader valuation context, see market value of IMMUNOCORE HLDGS ADS/1.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.20x | €26.06 Million | €5.17 Million | ▼ -89.2% |
| 2023 | 1.85x | €2.94 Million | €5.42 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow